Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Treasury Shares (2022 - 2025)

Edgewise Therapeutics has reported Treasury Shares over the past 4 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Treasury Shares at $1.3 million for Q4 2025, up 99.36% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (up 99.36% YoY), and the annual figure for FY2025 was $1.3 million, up 99.36%.
  • Treasury Shares reached $1.3 million in Q4 2025 per EWTX's latest filing, up from $639516.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.3 million in Q4 2025 and bottomed at $177871.0 in Q4 2023.
  • Median Treasury Shares over the past 4 years was $453545.5 (2022), compared with a mean of $589978.5.
  • The largest annual shift saw Treasury Shares plummeted 33.52% in 2023 before it surged 259.54% in 2024.
  • Over 4 years, Treasury Shares stood at $267575.0 in 2022, then tumbled by 33.52% to $177871.0 in 2023, then soared by 259.54% to $639516.0 in 2024, then skyrocketed by 99.36% to $1.3 million in 2025.
  • Business Quant data shows Treasury Shares for EWTX at $1.3 million in Q4 2025, $639516.0 in Q4 2024, and $177871.0 in Q4 2023.